Core Viewpoint - FLSmidth & Co. A/S is undergoing a significant transformation in its Board composition and strategic direction, focusing on growth in the mining industry following a successful operational restructuring [1][2][5]. Group 1: Board Changes - The company announced proposed changes to the Board composition ahead of the Annual General Meeting on 24 March 2026, including the Chair position [1]. - Chair Mads Nipper, Vice Chair Christian Bruch, and Board member Thrasyvoulos Moraitis will not seek re-election, reflecting the company's smaller and more focused structure [3]. - Lene Skole is proposed as the new Chair, bringing significant financial and strategic experience, while other members, including Rune Wichmann as proposed Vice Chair, will seek re-election [4]. Group 2: Strategic Transformation - FLSmidth has divested its Cement business and is now a pure-play supplier of technologies and services to the global mining industry, resulting in a more profitable company [1]. - The appointment of Toni Laaksonen as CEO aims to accelerate growth and further develop customer offerings, with plans for the next strategic phase to be revealed later this year [2]. - The company emphasizes its commitment to sustainability, aiming for zero emissions in mining by 2030 under its MissionZero initiative [7].

Group 1 - Nordecon AS and AS Tallinna Vesi have signed a contract for the construction of an additional building and infrastructure at the Ülemiste Water Treatment Plant site in Tallinn, with a total contract value of 11.8 million euros, plus VAT, to be completed by 2027 [1] - Nordecon is a group of construction companies focused on construction project management and general contracting in the buildings and infrastructures segment, operating in Estonia, Ukraine, and Sweden [2] - The consolidated revenue of Nordecon Group in 2025 was 208 million euros, and the company currently employs approximately 430 people [2]

Core Viewpoint - CoinShares has announced a permanent reduction in the management fee for its CoinShares Bitcoin ETP (BITC) to 0.15%, reinforcing its market leadership and commitment to accessible digital asset investment [1][3]. Group 1: Fee Reduction and Market Position - The management fee reduction positions BITC as one of the lowest-cost Bitcoin ETPs globally, enhancing its competitiveness in the European market [2][4]. - CoinShares aims to leverage its operational efficiency and market-leading scale to offer institutional-grade products at competitive prices [4]. Group 2: Commitment to Accessibility and Quality - The fee reduction aligns with CoinShares' belief that broad adoption of digital assets requires both institutional-quality products and accessible pricing [5]. - The new fee structure reflects the maturity of the Bitcoin market, ensuring that various investors, including portfolio managers and retail clients, have access to Bitcoin exposure at reasonable costs [6]. Group 3: Product Details - CoinShares Bitcoin ETP (BITC) is physically-backed and now has a management fee of 0.15%, effective immediately [9]. - The product is listed on multiple exchanges, including Xetra and the London Stock Exchange [9].

Core Viewpoint - KN is hosting an investor conference webinar on February 27, 2026, at 10:00 am (EET) to present its performance and unaudited financial results for the year 2025 [1]. Group 1: Webinar Details - The webinar will be led by KN's Chief Financial Officer, Tomas Tumėnas, who will discuss the company's financial performance [1]. - Participants are encouraged to submit questions in advance due to limited time during the webinar [2]. - Registration for the webinar is required, and a link is provided for participants to join [2]. Group 2: Corporate Webinar Definition - A corporate webinar is defined as a virtual conference where company representatives share information about the company's performance and allow for interactive communication [3].

Core Viewpoint - Pulsar Helium Inc. has successfully completed drilling Jetstream 6 at the Topaz Project in Minnesota, confirming the presence of multiple pressurized gas intervals and marking a significant milestone in the appraisal of the helium resource [5][6][10]. Group 1: Drilling Progress - Jetstream 6 has been drilled to a total depth of 2,597 feet, encountering multiple gas zones at depths of 1,287 feet (~576 psi), 2,120 feet (~981 psi), 2,187 feet (~1,012 psi), and 2,377 feet (~1,100 psi) [5][6]. - Drilling of Jetstream 7 has commenced, with a planned total depth of 3,000 feet and the potential to deepen to 5,000 feet, located 2.2 miles northwest of Jetstream 1 [7][10]. Group 2: Seismic Program - The extensive 2D active seismic acquisition program at the Topaz Project has been completed, consisting of five seismic lines totaling 41.5 miles [6][8]. - The raw seismic data has been reviewed by an independent expert and confirmed to be of good quality, with processing and interpretation now underway [9][10]. Group 3: Project Overview - The Topaz Helium Project is a large-scale exploration opportunity in Minnesota, with a 100% success rate in drilling appraisal wells that have intersected pressurized gas [10]. - The project has identified potentially saleable concentrations of helium, helium-3, and carbon dioxide, with helium-3 having strategic applications in various advanced technologies [10].

Core Insights - Urbo Bankas reported a net profit of EUR 5.5 million in 2025, which is 1.3 times lower than the EUR 7.4 million profit in 2024 [3] - The bank's total deposit portfolio increased by over 17% to EUR 655 million, while the loan portfolio grew by 31% to EUR 545 million [2][3] - Total assets reached EUR 740 million, a 17% increase from EUR 635 million the previous year [4] Financial Performance - Net interest income rose by 4% to EUR 23.9 million, despite a contraction in market interest margins [5] - The net result from foreign currency operations decreased by EUR 0.5 million to EUR 1.9 million, and net fee and commission income fell by EUR 0.7 million to EUR 2.9 million [6] - Shareholders' equity increased by 6% from EUR 64 million to EUR 68 million [4] Market Outlook - The CEO anticipates continued strong growth in 2026, driven by demand from small and medium-sized enterprises and growth in consumer and housing loans [7] - The Bank of Lithuania forecasts a GDP growth of 3.2% for the year, with rising average wages and declining inflation expected to support household consumption [8] - The bank employed 281 staff and operated 25 branches by the end of December 2025 [9]

Core Viewpoint - Equinor ASA announced a cash dividend of USD 0.37 per share for the third quarter of 2025, reflecting the company's ongoing commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The cash dividend per share for the third quarter of 2025 is set at USD 0.37 [1]. - The NOK equivalent of the cash dividend is calculated based on the average USDNOK fixing rate from Norges Bank, which was 9.5267, resulting in NOK 3.5249 per share [1]. Group 2: Payment Details - The cash dividend will be paid on 27 February 2026 to shareholders on the Oslo Børs and to holders of American Depositary Receipts (ADRs) on the New York Stock Exchange [2]. - This announcement complies with the Continuing Obligations and the disclosure requirements of the Norwegian Securities Trading Act [2].

Core Viewpoint - Equinor ASA announced a cash dividend of USD 0.37 per share for the third quarter of 2025, reflecting the company's ongoing commitment to returning value to shareholders [1]. Group 1: Dividend Announcement - The cash dividend per share for Q3 2025 is set at USD 0.37 [1]. - The corresponding NOK cash dividend per share is calculated to be NOK 3.5249, based on the average USDNOK fixing rate of 9.5267 from Norges Bank [1]. - The record date for the dividend is 17 February 2026, with the payment scheduled for 27 February 2026 [2]. Group 2: Payment Details - The cash dividend will be paid to shareholders on Oslo Børs and to holders of American Depositary Receipts (ADRs) on the New York Stock Exchange [2]. - This announcement complies with the Continuing Obligations and the disclosure requirements of the Norwegian Securities Trading Act [2].

Core Insights - Exosens has exceeded its 2025 revenue guidance with a strong growth of 22.1%, reaching €468.2 million, primarily driven by robust demand in the Defense and Surveillance sectors, which accounted for 75% of total revenue [4][13] - The company has demonstrated significant profitability improvements, with adjusted EBITDA increasing by 26.6% to €151.6 million, achieving a sector-leading margin of 32.4% [4][35] - Exosens is targeting continued double-digit growth in 2026, with projected revenue between €520 million and €540 million and adjusted EBITDA between €168 million and €178 million [46][52] Financial Performance - Revenue for 2025 was €468.2 million, up from €383.4 million in 2024, reflecting a 22.1% increase [10][13] - Adjusted gross margin rose to €234.0 million, a 24.2% increase from €188.4 million in 2024, with the margin percentage improving to 50.0% [31][10] - Net profit from continued operations more than doubled to €70.2 million, a 106.0% increase compared to €34.1 million in 2024 [38][39] Business Segments - Amplification revenue reached €319.2 million, representing 68% of total sales, with an 18.4% growth driven by increased demand for night vision applications [14][13] - Detection & Imaging revenue grew by 28.0% to €150.5 million, supported by acquisitions and strong performance in Defense and Surveillance markets [21][13] - The company completed three acquisitions in 2025, enhancing its capabilities in Surveillance and expanding its technology portfolio [7][19] Market Dynamics - The Defense sector is experiencing heightened demand for night vision technologies, particularly due to geopolitical tensions and evolving military requirements [15][16] - Exosens has secured significant contracts, including a €500 million deal with OCCAR for supplying night vision tubes to the German armed forces [16][7] - The company is investing €37 million to expand production capacity by 40% by 2027, targeting growth in both European and U.S. markets [17][46] Innovation and R&D - Exosens launched a breakthrough 5G image intensifier tube, improving performance benchmarks in night vision technology [18][7] - R&D expenses increased by 19.8% to €35.7 million, reflecting the company's commitment to innovation in imaging technologies [41][10] - The company is focused on developing advanced imaging systems for various sectors, including Defense, Industrial Control, Life Sciences, and Nuclear [41][7] Strategic Outlook - Exosens aims for medium-term organic revenue growth in the mid-teens and adjusted EBITDA growth above 15% [48][47] - The company plans to maintain a disciplined approach to capital allocation, focusing on long-term value creation through targeted acquisitions [50][51] - A proposed cash dividend of €0.30 per share for the 2025 fiscal year reflects the company's commitment to returning value to shareholders [45][51]

Core Insights - Novartis will present data on Rhapsido (remibrutinib), a selective oral Bruton's tyrosine kinase inhibitor, at the AAAAI Annual Meeting, focusing on its use in chronic spontaneous urticaria (CSU) and potential for peanut allergy treatment [1][2][3] Group 1: Clinical Data and Trials - New analyses from Phase III REMIX-1 and REMIX-2 trials will be presented, highlighting Rhapsido's impact on disease control and early symptom relief in CSU [2][6] - The first Phase II data on remibrutinib for IgE-mediated peanut allergy will be featured, with plans for a Phase III program in food allergy set for 2026 [2][3][6] - Positive topline results from the CIndU Phase III RemIND trial were announced, with FDA submission for symptomatic dermographism completed in Q4 2025 [4] Group 2: Regulatory and Market Potential - Regulatory reviews for remibrutinib in CSU are ongoing in regions including the European Union and Japan, indicating a strong commitment to expanding its market presence [3][4] - Novartis aims to address unmet needs in immune-mediated diseases, emphasizing the importance of innovative therapies for patients with limited alternatives [3][4] Group 3: Presentation Details - Accepted abstracts for presentation at the AAAAI include studies on the efficacy and safety of remibrutinib for peanut allergy and analyses from the REMIX studies on CSU [5][6] - Specific presentation times and formats are outlined, including oral and poster sessions scheduled from February 27 to March 1, 2026 [5][6]